Keloids – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Keloids – Pipeline Review, H2 2016’, provides an overview of the Keloids pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Keloids, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Keloids and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Keloids

The report reviews pipeline therapeutics for Keloids by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Keloids therapeutics and enlists all their major and minor projects

The report assesses Keloids therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Keloids

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Keloids

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Keloids pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

FirstString Research Inc

RXi Pharmaceuticals Corp

Topadur Pharma AG

Tumorend LLC

viDA Therapeutics Inc

Yuhan Corp

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Keloids Overview 6

Therapeutics Development 7

Pipeline Products for Keloids - Overview 7

Pipeline Products for Keloids - Comparative Analysis 8

Keloids - Therapeutics under Development by Companies 9

Keloids - Therapeutics under Investigation by Universities/Institutes 10

Keloids - Pipeline Products Glance 11

Clinical Stage Products 11

Early Stage Products 12

Keloids - Products under Development by Companies 13

Keloids - Products under Investigation by Universities/Institutes 14

Keloids - Companies Involved in Therapeutics Development 15

FirstString Research Inc 15

RXi Pharmaceuticals Corp 16

Topadur Pharma AG 17

Tumorend LLC 18

viDA Therapeutics Inc 19

Yuhan Corp 20

Keloids - Therapeutics Assessment 21

Assessment by Monotherapy Products 21

Assessment by Target 22

Assessment by Mechanism of Action 24

Assessment by Route of Administration 26

Assessment by Molecule Type 28

Drug Profiles 30

CM-101 - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

Granexin - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

koebnerisin - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

psoriasin - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

RXI-109 - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

TOPN-44 - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

V-2248 - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

VTI-3000 Series - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

YH-siRNA1 - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

Keloids - Dormant Projects 45

Keloids - Discontinued Products 46

Keloids - Product Development Milestones 47

Featured News & Press Releases 47

Jun 02, 2015: RXi Pharmaceuticals to Present at the 23rd World Congress of Dermatology 47

Apr 29, 2014: RXi Pharmaceuticals Announces Initiation of Phase 2a Keloid Study 47

Mar 05, 2014: RXi Pharmaceuticals Granted Key Patent Related to Self-Delivering Technology for the Treatment of Fibrotic Disorders 48

Dec 04, 2013: RXi Pharmaceuticals Announces mRNA Data of an Additional Cohort in the Second Phase 1 Multi-Dose Study with RXI-109, Extending the Dose Response Following Treatment in the Initial 2-week Period 48

Nov 18, 2013: RXi Pharmaceuticals and Ethicor Announce the Signing of a Distribution Agreement for RXI-109 in the European Union under the "Specials" Provision 49

Jun 06, 2013: RXi Pharmaceuticals Announces Positive Results In First Double Blind Study In Healthy Volunteers With RXI-109 49

Jan 30, 2013: RXi Pharma Completes Enrollment In Second Phase I Trial For RXI-109 Program 50

Appendix 52

Methodology 52

Coverage 52

Secondary Research 52

Primary Research 52

Expert Panel Validation 52

Contact Us 52

Disclaimer 53

List of Tables

List of Tables

Number of Products under Development for Keloids, H2 2016 7

Number of Products under Development for Keloids – Comparative Analysis, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Number of Products under Investigation by Universities/Institutes, H2 2016 10

Comparative Analysis by Clinical Stage Development, H2 2016 11

Comparative Analysis by Early Stage Development, H2 2016 12

Products under Development by Companies, H2 2016 13

Products under Investigation by Universities/Institutes, H2 2016 14

Keloids – Pipeline by FirstString Research Inc, H2 2016 15

Keloids – Pipeline by RXi Pharmaceuticals Corp, H2 2016 16

Keloids – Pipeline by Topadur Pharma AG, H2 2016 17

Keloids – Pipeline by Tumorend LLC, H2 2016 18

Keloids – Pipeline by viDA Therapeutics Inc, H2 2016 19

Keloids – Pipeline by Yuhan Corp, H2 2016 20

Assessment by Monotherapy Products, H2 2016 21

Number of Products by Stage and Target, H2 2016 23

Number of Products by Stage and Mechanism of Action, H2 2016 25

Number of Products by Stage and Route of Administration, H2 2016 27

Number of Products by Stage and Molecule Type, H2 2016 29

Keloids – Dormant Projects, H2 2016 45

Keloids – Discontinued Products, H2 2016 46

List of Figures

List of Figures

Number of Products under Development for Keloids, H2 2016 7

Number of Products under Development for Keloids – Comparative Analysis, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Comparative Analysis by Early Stage Products, H2 2016 12

Assessment by Monotherapy Products, H2 2016 21

Number of Products by Targets, H2 2016 22

Number of Products by Stage and Targets, H2 2016 22

Number of Products by Mechanism of Actions, H2 2016 24

Number of Products by Stage and Mechanism of Actions, H2 2016 24

Number of Products by Routes of Administration, H2 2016 26

Number of Products by Stage and Routes of Administration, H2 2016 26

Number of Products by Molecule Types, H2 2016 28

Number of Products by Stage and Molecule Types, H2 2016 28

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports